Neuroblastoom (Dutch Wikipedia)

Analysis of information sources in references of the Wikipedia article "Neuroblastoom" in Dutch language version.

refsWebsite

Global rank Dutch rank

28nih.gov

4^th place

12^th place

25doi.org

2^nd place

8^th place

4elsevier.com

610^th place

1,231^st place

3archive.org

6^th place

25^th place

3web.archive.org

1^st place

3nejm.org

2,374^th place

1,153^rd place

3cancer.gov

1,684^th place

7,668^th place

2ascopubs.org

low place

1erfelijkheid.nl

low place

2,104^th place

1sciencedirect.com

149^th place

200^th place

1emedicine.com

3,595^th place

8,320^th place

1cancerbackup.org.uk

low place

1merck.com

6,464^th place

3,767^th place

1elsevierhealth.com

low place

1snmjournals.org

low place

1slate.com

259^th place

597^th place

1cambridge.org

305^th place

562^nd place

1asco.org

low place

1ajc.com

685^th place

6,509^th place

1oxfordjournals.org

1,389^th place

539^th place

1jco.org

low place

ajc.com

"Childhood Cancer Survivors Face Increased Sarcoma Risk", HealthDay News, February 21, 2007

archive.org

Cheung, Nai-Kong (2005). Neuroblastoma. Springer-Verlag. ISBN 3-540-40841-X.
Cheung, Nai-Kong (2005). Neuroblastoma. Springer-Verlag. ISBN 3-540-40841-X.
Cheung, Nai-Kong (2005). Neuroblastoma. Springer-Verlag. ISBN 3-540-40841-X.

asco.org

abstract.asco.org

A phase III randomized trial of the chimeric anti-GD2 antibody ch14.18 with GM-CSF and IL2 as immunotherapy following dose intensive chemotherapy for high-risk neuroblastoma: Children’s Oncology Group (COG) study ANBL0032.

ascopubs.org

jco.ascopubs.org

Schmidt ML, Lal A, Seeger RC, Maris JM, Shimada H, O'Leary M, Gerbing RB, Matthay KK (2005). Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study. J Clin Oncol 23 (27): 6474–80. PMID 16116154. DOI: 10.1200/JCO.2005.05.183.
Reduction From Seven to Five Cycles of Intensive Induction Chemotherapy in Children With High-Risk Neuroblastoma -- Kushner et al. 22 (24): 4888 -- Journal of Clinical Oncology.

cambridge.org

journals.cambridge.org

Johnson E, Dean SM, Sondel PM (2007). Antibody-based immunotherapy in high-risk neuroblastoma (abstract). Expert Rev Mol Med 9 (34): 1–21. PMID 18081947. DOI: 10.1017/S1462399407000518.

cancer.gov

Neuroblastoma Screening - National Cancer Institute. Geraadpleegd op 30 juli 2008.
Neuroblastoma Treatment - National Cancer Institute. Geraadpleegd op 2 februari 2008.
Neuroblastoma Treatment - National Cancer Institute. Geraadpleegd op 30 juli 2008.

cancerbackup.org.uk

Neuroblastoma in children : Cancerbackup. Geraadpleegd op 1 januari 2008.

doi.org

Bénard J, Raguénez G, Kauffmann A, et al. (October 2008). MYCN-non-amplified metastatic neuroblastoma with good prognosis and spontaneous regression: a molecular portrait of stage 4S. Mol Oncol 2 (3): 261–71. PMID 19383347. DOI: 10.1016/j.molonc.2008.07.002.
Friedman GK, Castleberry RP (December 2007). Changing trends of research and treatment in infant neuroblastoma. Pediatr Blood Cancer 49 (7 Suppl): 1060–5. PMID 17943963. DOI: 10.1002/pbc.21354.
Rothenberg AB, Berdon WE, D'Angio GJ, Yamashiro DJ, Cowles RA (July 2009). The association between neuroblastoma and opsoclonus-myoclonus syndrome: a historical review. Pediatr Radiol 39 (7): 723–6. PMID 19430769. DOI: 10.1007/s00247-009-1282-x.
Mossé YP, Laudenslager M, Longo L, et al. (October 2008). Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 455 (7215): 930–5. PMID 18724359. PMC 2672043. DOI: 10.1038/nature07261.
Strenger V, Kerbl R, Dornbusch HJ, et al. (2007). Diagnostic and prognostic impact of urinary catecholamines in neuroblastoma patients. Pediatr Blood Cancer 48 (5): 504–9. PMID 16732582. DOI: 10.1002/pbc.20888.
Howman-Giles R, Shaw PJ, Uren RF, Chung DK (2007). Neuroblastoma and other neuroendocrine tumors. Semin Nucl Med 37 (4): 286–302. PMID 17544628. DOI: 10.1053/j.semnuclmed.2007.02.009.
Peuchmaur M, d'Amore ES, Joshi VV, et al. (2003). Revision of the International Neuroblastoma Pathology Classification: confirmation of favorable and unfavorable prognostic subsets in ganglioneuroblastoma, nodular. Cancer 98 (10): 2274–81. PMID 14601099. DOI: 10.1002/cncr.11773.
Schmidt ML, Lal A, Seeger RC, Maris JM, Shimada H, O'Leary M, Gerbing RB, Matthay KK (2005). Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study. J Clin Oncol 23 (27): 6474–80. PMID 16116154. DOI: 10.1200/JCO.2005.05.183.
Maris JM, Hogarty MD, Bagatell R, Cohn SL (2007). Neuroblastoma. The Lancet 369 (9579): 2106–20. PMID 17586306. DOI: 10.1016/S0140-6736(07)60983-0.
Woods WG, Gao RN, Shuster JJ, et al. (2002). Screening of infants and mortality due to neuroblastoma. N. Engl. J. Med. 346 (14): 1041–6. PMID 11932470. DOI: 10.1056/NEJMoa012387.
Schilling FH, Spix C, Berthold F, et al. (2003). Children may not benefit from neuroblastoma screening at 1 year of age. Updated results of the population based controlled trial in Germany. Cancer Lett. 197 (1-2): 19–28. PMID 12880955. DOI: 10.1016/S0304-3835(03)00077-6.
Tsubono Y, Hisamichi S (2004). A halt to neuroblastoma screening in Japan. N. Engl. J. Med. 350 (19): 2010–1. PMID 15128908. DOI: 10.1056/NEJM200405063501922.
Johnson E, Dean SM, Sondel PM (2007). Antibody-based immunotherapy in high-risk neuroblastoma (abstract). Expert Rev Mol Med 9 (34): 1–21. PMID 18081947. DOI: 10.1017/S1462399407000518.
Gisselsson D, Lundberg G, Ora I, Höglund M (2007). Distinct evolutionary mechanisms for genomic imbalances in high-risk and low-risk neuroblastomas. J Carcinog 6: 15. PMID 17897457. PMC 2042979. DOI: 10.1186/1477-3163-6-15.
Haase GM, Perez C, Atkinson JB (1999). Current aspects of biology, risk assessment, and treatment of neuroblastoma. Semin Surg Oncol 16 (2): 91–104. PMID 9988866. DOI: <91::AID-SSU3>3.0.CO;2-1 10.1002/(SICI)1098-2388(199903)16:2<91::AID-SSU3>3.0.CO;2-1.
Fish JD, Grupp SA (2007). Stem cell transplantation for neuroblastoma. Bone Marrow Transplant 41 (2): 159. PMID 18037943. PMC 2892221. DOI: 10.1038/sj.bmt.1705929.
Matthay KK, Villablanca JG, Seeger RC, et al. (1999). Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N. Engl. J. Med. 341 (16): 1165–73. PMID 10519894. DOI: 10.1056/NEJM199910143411601.
Yu AL, Gilman AL, Ozkaynak MF, et al. (September 2010). Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N. Engl. J. Med. 363 (14): 1324–34. PMID 20879881. DOI: 10.1056/NEJMoa0911123.
Ceschel S, Casotto V, Valsecchi MG, et al. (Oct 2006). Survival after relapse in children with solid tumors: a follow-up study from the Italian off-therapy registry. Pediatr Blood Cancer 47 (5): 560–6. PMID 16395684. DOI: 10.1002/pbc.20726.
Gurney JG, Tersak JM, Ness KK, Landier W, Matthay KK, Schmidt ML (2007). Hearing loss, quality of life, and academic problems in long-term neuroblastoma survivors: a report from the Children's Oncology Group. Pediatrics 120 (5): e1229–36. PMID 17974716. DOI: 10.1542/peds.2007-0178.
Trahair TN, Vowels MR, Johnston K, Cohn RJ, Russell SJ, Neville KA, Carroll S, Marshall GM (2007). Long-term outcomes in children with high-risk neuroblastoma treated with autologous stem cell transplantation. Bone Marrow Transplant 40 (8): 741–6. PMID 17724446. DOI: 10.1038/sj.bmt.1705809.
Janoueix-Lerosey I, Schleiermacher G, Michels E, et al. (March 2009). Overall genomic pattern is a predictor of outcome in neuroblastoma. J. Clin. Oncol. 27 (7): 1026–33. PMID 19171713. DOI: 10.1200/JCO.2008.16.0630.
Franks LM, Bollen A, Seeger RC, Stram DO, Matthay KK (1997). Neuroblastoma in adults and adolescents: an indolent course with poor survival. Cancer 79 (10): 2028–35. PMID 9149032. DOI: <2028::AID-CNCR26>3.0.CO;2-V 10.1002/(SICI)1097-0142(19970515)79:10<2028::AID-CNCR26>3.0.CO;2-V.
Ladenstein R, Pötschger U, Hartman O, et al. (June 2008). 28 years of high-dose therapy and SCT for neuroblastoma in Europe: lessons from more than 4000 procedures. Bone Marrow Transplant. 41 Suppl 2: S118–27. PMID 18545256. DOI: 10.1038/bmt.2008.69.
Rothenberg AB, Berdon WE, D'Angio GJ, Yamashiro DJ, Cowles RA (February 2009). Neuroblastoma-remembering the three physicians who described it a century go: James Homer Wright, William Pepper, and Robert Hutchison. Pediatr Radiol 39 (2): 155–60. PMID 19034443. DOI: 10.1007/s00247-008-1062-z.

elsevier.com

linkinghub.elsevier.com

Bénard J, Raguénez G, Kauffmann A, et al. (October 2008). MYCN-non-amplified metastatic neuroblastoma with good prognosis and spontaneous regression: a molecular portrait of stage 4S. Mol Oncol 2 (3): 261–71. PMID 19383347. DOI: 10.1016/j.molonc.2008.07.002.
Howman-Giles R, Shaw PJ, Uren RF, Chung DK (2007). Neuroblastoma and other neuroendocrine tumors. Semin Nucl Med 37 (4): 286–302. PMID 17544628. DOI: 10.1053/j.semnuclmed.2007.02.009.
Maris JM, Hogarty MD, Bagatell R, Cohn SL (2007). Neuroblastoma. The Lancet 369 (9579): 2106–20. PMID 17586306. DOI: 10.1016/S0140-6736(07)60983-0.
Schilling FH, Spix C, Berthold F, et al. (2003). Children may not benefit from neuroblastoma screening at 1 year of age. Updated results of the population based controlled trial in Germany. Cancer Lett. 197 (1-2): 19–28. PMID 12880955. DOI: 10.1016/S0304-3835(03)00077-6.

elsevierhealth.com

us.elsevierhealth.com

Olshan, AF, Bunin, GR (2000) Epidemiology of Neuroblastoma. In: Brodeur, GM, Sawada, T, Tsuchida, Y, Voute, PA eds. , Neuroblastoma, Elsevier, Amsterdam, pp 33-39. ISBN 044450222X

emedicine.com

eMedicine - Esthesioneuroblastoma : Article by Pavel Dulguerov, MD. Geraadpleegd op 30 juli 2008.

erfelijkheid.nl

Erfelijkheid.nl - Neuroblastoom. Geraadpleegd op 21 september 2011.

jco.org

Janoueix-Lerosey I, Schleiermacher G, Michels E, et al. (March 2009). Overall genomic pattern is a predictor of outcome in neuroblastoma. J. Clin. Oncol. 27 (7): 1026–33. PMID 19171713. DOI: 10.1200/JCO.2008.16.0630.

merck.com

Neuroblastoma: Pediatric Cancers: Merck Manual Professional. Geraadpleegd op 1 januari 2008.

nejm.org

content.nejm.org

Woods WG, Gao RN, Shuster JJ, et al. (2002). Screening of infants and mortality due to neuroblastoma. N. Engl. J. Med. 346 (14): 1041–6. PMID 11932470. DOI: 10.1056/NEJMoa012387.
Matthay KK, Villablanca JG, Seeger RC, et al. (1999). Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N. Engl. J. Med. 341 (16): 1165–73. PMID 10519894. DOI: 10.1056/NEJM199910143411601.
Oeffinger et al., "Chronic Health Conditions in Adult Survivors of Childhood Cancer", New England Journal of Medicine, October 12, 2006

nih.gov

ncbi.nlm.nih.gov

Bénard J, Raguénez G, Kauffmann A, et al. (October 2008). MYCN-non-amplified metastatic neuroblastoma with good prognosis and spontaneous regression: a molecular portrait of stage 4S. Mol Oncol 2 (3): 261–71. PMID 19383347. DOI: 10.1016/j.molonc.2008.07.002.
Friedman GK, Castleberry RP (December 2007). Changing trends of research and treatment in infant neuroblastoma. Pediatr Blood Cancer 49 (7 Suppl): 1060–5. PMID 17943963. DOI: 10.1002/pbc.21354.
Rothenberg AB, Berdon WE, D'Angio GJ, Yamashiro DJ, Cowles RA (July 2009). The association between neuroblastoma and opsoclonus-myoclonus syndrome: a historical review. Pediatr Radiol 39 (7): 723–6. PMID 19430769. DOI: 10.1007/s00247-009-1282-x.
Mossé YP, Laudenslager M, Longo L, et al. (October 2008). Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 455 (7215): 930–5. PMID 18724359. PMC 2672043. DOI: 10.1038/nature07261.
Strenger V, Kerbl R, Dornbusch HJ, et al. (2007). Diagnostic and prognostic impact of urinary catecholamines in neuroblastoma patients. Pediatr Blood Cancer 48 (5): 504–9. PMID 16732582. DOI: 10.1002/pbc.20888.
Howman-Giles R, Shaw PJ, Uren RF, Chung DK (2007). Neuroblastoma and other neuroendocrine tumors. Semin Nucl Med 37 (4): 286–302. PMID 17544628. DOI: 10.1053/j.semnuclmed.2007.02.009.
Pashankar F,O’Dorisio M, Menda Y (2005). MIBG and somatostatin receptor analogs in children: current concepts on diagnostic and therapeutic use. Journal of Nuclear Medicine 46 (1 (suppl)): 55S–61S. PMID 15653652.
Peuchmaur M, d'Amore ES, Joshi VV, et al. (2003). Revision of the International Neuroblastoma Pathology Classification: confirmation of favorable and unfavorable prognostic subsets in ganglioneuroblastoma, nodular. Cancer 98 (10): 2274–81. PMID 14601099. DOI: 10.1002/cncr.11773.
Schmidt ML, Lal A, Seeger RC, Maris JM, Shimada H, O'Leary M, Gerbing RB, Matthay KK (2005). Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study. J Clin Oncol 23 (27): 6474–80. PMID 16116154. DOI: 10.1200/JCO.2005.05.183.
Maris JM, Hogarty MD, Bagatell R, Cohn SL (2007). Neuroblastoma. The Lancet 369 (9579): 2106–20. PMID 17586306. DOI: 10.1016/S0140-6736(07)60983-0.
Woods WG, Gao RN, Shuster JJ, et al. (2002). Screening of infants and mortality due to neuroblastoma. N. Engl. J. Med. 346 (14): 1041–6. PMID 11932470. DOI: 10.1056/NEJMoa012387.
Schilling FH, Spix C, Berthold F, et al. (2003). Children may not benefit from neuroblastoma screening at 1 year of age. Updated results of the population based controlled trial in Germany. Cancer Lett. 197 (1-2): 19–28. PMID 12880955. DOI: 10.1016/S0304-3835(03)00077-6.
Tsubono Y, Hisamichi S (2004). A halt to neuroblastoma screening in Japan. N. Engl. J. Med. 350 (19): 2010–1. PMID 15128908. DOI: 10.1056/NEJM200405063501922.
Johnson E, Dean SM, Sondel PM (2007). Antibody-based immunotherapy in high-risk neuroblastoma (abstract). Expert Rev Mol Med 9 (34): 1–21. PMID 18081947. DOI: 10.1017/S1462399407000518.
Neuroblastoma: biological insights into a clinical enigma. Brodeur GM. Nature Reviews Cancer. 2003 Mar;3(3):203-16. PMID 12612655
Gisselsson D, Lundberg G, Ora I, Höglund M (2007). Distinct evolutionary mechanisms for genomic imbalances in high-risk and low-risk neuroblastomas. J Carcinog 6: 15. PMID 17897457. PMC 2042979. DOI: 10.1186/1477-3163-6-15.
Haase GM, Perez C, Atkinson JB (1999). Current aspects of biology, risk assessment, and treatment of neuroblastoma. Semin Surg Oncol 16 (2): 91–104. PMID 9988866. DOI: <91::AID-SSU3>3.0.CO;2-1 10.1002/(SICI)1098-2388(199903)16:2<91::AID-SSU3>3.0.CO;2-1.
Fish JD, Grupp SA (2007). Stem cell transplantation for neuroblastoma. Bone Marrow Transplant 41 (2): 159. PMID 18037943. PMC 2892221. DOI: 10.1038/sj.bmt.1705929.
Matthay KK, Villablanca JG, Seeger RC, et al. (1999). Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N. Engl. J. Med. 341 (16): 1165–73. PMID 10519894. DOI: 10.1056/NEJM199910143411601.
Yu AL, Gilman AL, Ozkaynak MF, et al. (September 2010). Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N. Engl. J. Med. 363 (14): 1324–34. PMID 20879881. DOI: 10.1056/NEJMoa0911123.
Ceschel S, Casotto V, Valsecchi MG, et al. (Oct 2006). Survival after relapse in children with solid tumors: a follow-up study from the Italian off-therapy registry. Pediatr Blood Cancer 47 (5): 560–6. PMID 16395684. DOI: 10.1002/pbc.20726.
Gurney JG, Tersak JM, Ness KK, Landier W, Matthay KK, Schmidt ML (2007). Hearing loss, quality of life, and academic problems in long-term neuroblastoma survivors: a report from the Children's Oncology Group. Pediatrics 120 (5): e1229–36. PMID 17974716. DOI: 10.1542/peds.2007-0178.
Trahair TN, Vowels MR, Johnston K, Cohn RJ, Russell SJ, Neville KA, Carroll S, Marshall GM (2007). Long-term outcomes in children with high-risk neuroblastoma treated with autologous stem cell transplantation. Bone Marrow Transplant 40 (8): 741–6. PMID 17724446. DOI: 10.1038/sj.bmt.1705809.
Janoueix-Lerosey I, Schleiermacher G, Michels E, et al. (March 2009). Overall genomic pattern is a predictor of outcome in neuroblastoma. J. Clin. Oncol. 27 (7): 1026–33. PMID 19171713. DOI: 10.1200/JCO.2008.16.0630.
Franks LM, Bollen A, Seeger RC, Stram DO, Matthay KK (1997). Neuroblastoma in adults and adolescents: an indolent course with poor survival. Cancer 79 (10): 2028–35. PMID 9149032. DOI: <2028::AID-CNCR26>3.0.CO;2-V 10.1002/(SICI)1097-0142(19970515)79:10<2028::AID-CNCR26>3.0.CO;2-V.
Ladenstein R, Pötschger U, Hartman O, et al. (June 2008). 28 years of high-dose therapy and SCT for neuroblastoma in Europe: lessons from more than 4000 procedures. Bone Marrow Transplant. 41 Suppl 2: S118–27. PMID 18545256. DOI: 10.1038/bmt.2008.69.
Rothenberg AB, Berdon WE, D'Angio GJ, Yamashiro DJ, Cowles RA (February 2009). Neuroblastoma-remembering the three physicians who described it a century go: James Homer Wright, William Pepper, and Robert Hutchison. Pediatr Radiol 39 (2): 155–60. PMID 19034443. DOI: 10.1007/s00247-008-1062-z.

pubmedcentral.nih.gov

In Situ Neuroblastomas: a Contribution to the Natural History of Neural Crest Tumors.

oxfordjournals.org

jnci.oxfordjournals.org

Long-term Outcomes in Survivors of Neuroblastoma: A Report From the Childhood Cancer Survivor Study -- Laverdière et al., 10.1093/jnci/djp230 -- JNCI Journal of the National Cancer Institute.

sciencedirect.com

ScienceDirect - The Lancet : Neuroblastoma^{[dode link]}.

slate.com

Darshak Sanghavi, "Screen Alert: How an Ounce of RX Prevention can Cause a Pound of Hurt", Slate magazine, November 28, 2006

snmjournals.org

jnm.snmjournals.org

Pashankar F,O’Dorisio M, Menda Y (2005). MIBG and somatostatin receptor analogs in children: current concepts on diagnostic and therapeutic use. Journal of Nuclear Medicine 46 (1 (suppl)): 55S–61S. PMID 15653652.

web.archive.org

Cohn SL, London WB, Monclair T, Matthay KK, Ambros PF, Pearson AD, for the INRG Working Group (2007). Update on the development of the international neuroblastoma risk group (INRG) classification schema (abstract). Journal of Clinical Oncology 2007 ASCO Annual Meeting Proceedings Part 1 25 (18S). Gearchiveerd van origineel op 23 december 2008. Geraadpleegd op 28 mei 2019.
Translating Neuroblastoma Genomics to the Clinic - J. Maris presentation ASCO 2007. Gearchiveerd op 2 januari 2009. Geraadpleegd op 13 januari 2008.
Response and toxicity to a dose-intensive multi-agent chemotherapy induction regimen for high risk neuroblastoma (HR-NB): A Children's Oncology Group (COG A3973) study. - ASCO. Gearchiveerd op 3 januari 2009. Geraadpleegd op 2 februari 2008.